

CHROMAVISION MEDICAL SYSTEMS INC
Form SC 13D/A
August 13, 2002

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 3) (1)

ChromaVision Medical Systems, Inc.
(Name of Issuer)

Common Stock, \$0.01 Par Value Per Share
(Title of Class of Securities)

17111P 10 4
(CUSIP Number)

N. Jeffrey Klauder, Esq.
800 The Safeguard Building, 435 Devon Park Drive
Wayne, PA 19087-1945
(610) 293-0600
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)

July 9, 2002
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box / /.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

(continued on following pages)

(1) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section of the Exchange Act but shall be subject to all other provisions of the Exchange Act.

CUSIP No. 17111P 10 4

13D

Page 2 of 14

1 NAME OF REPORTING PERSON
Safeguard Scientifics, Inc.

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
23-1609753

Edgar Filing: CHROMAVISION MEDICAL SYSTEMS INC - Form SC 13D/A

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) / /
 (b) / /
 3 SEC USE ONLY
 4 SOURCE OF FUNDS
 WC
 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
 REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) / /
 6 CITIZENSHIP OR PLACE OF ORGANIZATION
 Pennsylvania

NUMBER OF 7 SOLE VOTING POWER
 SHARES -0-
 BENEFICIALLY
 OWNED BY 8 SHARED VOTING POWER
 EACH 14,919,415
 PERSON WITH
 9 SOLE DISPOSITIVE POWER
 -0-
 10 SHARED DISPOSITIVE POWER
 13,958,493

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 14,919,415

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
 CERTAIN SHARES* / x /

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 52.7%

14 TYPE OF REPORTING PERSON
 CO

* Excludes an aggregate of 45,915 shares of common stock held by certain executive officers and directors of Safeguard Scientifics, Inc. and 501(c)(3) foundations, trusts and limited partnerships that are either controlled by them or over which they exercise shared voting or dispositive power. Safeguard Scientifics, Inc. disclaims beneficial ownership of such shares.

CUSIP No. 17111P 10 4

13D

Page 3 of 14

1 NAME OF REPORTING PERSON
 Safeguard Delaware, Inc.
 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
 52-2081181

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) / /
 (b) / /
 3 SEC USE ONLY
 4 SOURCE OF FUNDS

Edgar Filing: CHROMAVISION MEDICAL SYSTEMS INC - Form SC 13D/A

AF

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) / /

6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON	7	SOLE VOTING POWER -0-
	8	SHARED VOTING POWER * 11,480,694
	9	SOLE DISPOSITIVE POWER -0-
	10	SHARED DISPOSITIVE POWER 10,519,772

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11,480,694

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / /

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
40.5%

14 TYPE OF REPORTING PERSON
CO

*Pursuant to Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended, the filing persons may have acquired beneficial ownership of 960,922 shares of ChromaVision Medical Systems, Inc. common stock by virtue of voting agreements and irrevocable proxies which are described in Amendment No. 2 to Schedule 13D previously filed by Safeguard Scientifics, Inc.

CUSIP No. 17111P 10 4

13D

Page 4 of 14

1 NAME OF REPORTING PERSON
Safeguard Scientifics (Delaware), Inc.

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
51-0291171

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) / /
(b) / /

3 SEC USE ONLY

4 SOURCE OF FUNDS
AF

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) / /

6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

NUMBER OF	7	SOLE VOTING POWER
-----------	---	-------------------

Edgar Filing: CHROMAVISION MEDICAL SYSTEMS INC - Form SC 13D/A

SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON -0-

8	SHARED VOTING POWER	3,438,721
9	SOLE DISPOSITIVE POWER	-0-
10	SHARED DISPOSITIVE POWER	3,438,721

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,438,721

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / /

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
13.6%

14 TYPE OF REPORTING PERSON
CO

CUSIP No. 17111P 10 4 13D Page 5 of 14

1 NAME OF REPORTING PERSON
Safeguard 98 Capital, L.P.

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
52-2081182

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) / /
(b) / /

3 SEC USE ONLY

4 SOURCE OF FUNDS
AF

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) / /

6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

7	SOLE VOTING POWER	-0-
8	SHARED VOTING POWER	-0-
9	SOLE DISPOSITIVE POWER	-0-
10	SHARED DISPOSITIVE POWER	-0-

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
-0-

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES

Edgar Filing: CHROMAVISION MEDICAL SYSTEMS INC - Form SC 13D/A

CERTAIN SHARES*

/ /

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0%

14 TYPE OF REPORTING PERSON
PN

Page 6 of 14

The following information supplements and amends the information contained in the Schedule 13D and amendments thereto previously filed by Safeguard Scientifics, Inc. ("Safeguard") relating to the ownership by its subsidiaries of the common stock, \$0.01 par value per share, of ChromaVision Medical Systems, Inc., a Delaware corporation (the "Company"), listed on the cover pages of this amendment.

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

Add the following to the end of Item 3:

On June 30, 2002, pursuant to the terms of the Series D Preferred Stock, the Company elected to pay the dividend on the Series D Stock in common stock and delivered to SDI 114,992 shares of common stock based on a per share value of \$1.786.

Pursuant to the terms of the Securities Purchase Agreement dated June __, 2002, to which Safeguard Delaware, Inc. (SDI) and XL Vision, Inc. (XLV) were parties, SDI agreed to purchase from XLV the 699,870 shares of Company common stock owned by XLV. The transaction was subject to the approval of the United States Bankruptcy Court of the Southern District of Florida, in the matter of XL Vision, Inc., Debtor. The Bankruptcy Court approved the transaction on July 8, 2002, and on July 9, 2002, SDI purchased the 699,870 shares of Company common stock at a per share purchase price of \$1.585. Safeguard 98 Capital, L.P. had a pre-existing right to obtain from XLV 324,612 shares of Company common stock under the convertible note issued by XLV. Since XLV no longer owns shares of Company common stock, the convertible note held by Safeguard 98 Capital, L.P. will remain outstanding as a claim against the XLV bankruptcy estate although XLV no longer owns shares of Company common stock to deliver upon the conversion. The funds used in making such purchase came from the general working capital of Safeguard.

ITEM 4. PURPOSE OF TRANSACTION

Safeguard acquired the shares as part of its operating strategy to integrate its partner companies into a collaborative network that leverages its collective knowledge and resources. With the goal of holding its partner company interests for the long term, Safeguard uses these collective resources to actively develop the business strategies, operations and management teams of the Company and its other partner companies. Safeguard intends to review, from time to time, its interest in the Company's business, financial condition, results of operations and prospects, economic and industry conditions, as well as other developments and other acquisition opportunities. Based upon these considerations, Safeguard may seek to acquire additional shares of common stock of the Company on the open market or in privately negotiated transactions, or to dispose of all or a portion of its shares of the Company, subject to certain restrictions described in Amendment No. 2 to Schedule 13D.

Safeguard has a strategic relationship with the Company and, accordingly, one representative of Safeguard is currently a member of the Board of Directors of the Company. Safeguard anticipates that this strategic relationship will continue.

Edgar Filing: CHROMAVISION MEDICAL SYSTEMS INC - Form SC 13D/A

Other than as set forth in Item 3 or Item 4 of this statement or as disclosed in previous amendments to Schedule 13D, each Reporting Person currently has no plan or proposal which relates to, or may result in, any of the matters listed in Items 4(a) - (i) of Schedule 13D (although each Reporting Person reserves the right to develop such plans).

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

Replace the disclosure previously contained in Item 5 with the following:

The table below sets forth the aggregate number of shares and percentage of the Company's outstanding shares beneficially owned by each Reporting Person as of July 9, 2002. The information contained in rows 6 through 11 on each of the cover pages hereto is hereby incorporated by reference into this Item 5.

Unless otherwise indicated in Schedule V annexed hereto, no Reporting Person or director or executive officer of a Reporting Person listed on Schedules II through IV annexed hereto has consummated any transaction in the Company's shares during the past sixty days other than as set forth herein.

Page 7 of 14

	Beneficial Ownersh -----
	Number of Shares -----
Safeguard Scientifics, Inc. (2)	14,919,415
Safeguard Delaware, Inc. (3)	11,480,694
Safeguard Scientifics (Delaware), Inc.	3,438,721
Safeguard 98 Capital L.P.	0

- (1) Calculations based upon 25,301,970 shares outstanding.
- (2) Includes the 7,523,977 directly held shares, the 2,955,745 shares of common stock currently issuable upon the conversion of the Series D Preferred Stock, and warrants to purchase 40,050 shares beneficially owned by Safeguard Delaware, Inc. (SDI) and the 3,438,721 shares beneficially owned by Safeguard Scientifics (Delaware), Inc. (SSD). Includes the 960,922 shares that may be beneficially owned by SDI by virtue of voting agreements and irrevocable proxies previously described in Amendment No. 2 to Schedule 13D. Safeguard is the sole stockholder of each of SDI and SSD. Safeguard and each of SDI and SSD have reported that Safeguard, together with each of SDI and SSD, respectively, have shared voting and dispositive power with respect to the shares beneficially owned by each of SDI and SSD, respectively. Excludes (i) an aggregate of 45,915 shares of common stock held by certain executive officers and directors of Reporting Persons and 501(c)(3) foundations, trusts and limited partnerships that are either controlled by them or over which they exercise shared voting or dispositive power, of which Safeguard disclaims beneficial ownership, (ii) 362,663 shares of common stock that SDI has the right to purchase from the Company under stockholder approval, and (iii) 4,151,294 additional shares of common stock issuable to SDI upon conversion of all of the outstanding shares of Series D Preferred Stock and/or exercise of the Series D Warrants upon stockholder approval.
- (3) Includes warrants to purchase 40,050 shares. Includes the 960,922

Edgar Filing: CHROMAVISION MEDICAL SYSTEMS INC - Form SC 13D/A

shares that may be beneficially owned by SDI by virtue of voting agreements and irrevocable proxies previously described in Amendment No. 2 to Schedule 13D. See Note 2.

ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER

In addition to the agreements previously filed as exhibits to Schedule 13D and amendments thereto, SDI and XLV are parties to the Stock Purchase Agreement dated as of June __, 2002, pursuant to which SDI acquired the shares set forth in Items 3 and 4 above from XLV.

Item 7. MATERIAL TO BE FILED AS EXHIBITS

EXHIBIT NO. -----	DESCRIPTION -----
99.13	Stock Purchase Agreement dated as of June __, 2002 between Safeguard Delaware, Inc. and XL Vision, Inc.

Page 8 of 14

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this schedule is true, complete and correct.

Date: August 2, 2002	Safeguard Scientifics, Inc. By: /s/ N. Jeffrey Klauder ----- N. Jeffrey Klauder Managing Director
Date: August 2, 2002	Safeguard Delaware, Inc. By: /s/ N. Jeffrey Klauder ----- N. Jeffrey Klauder Vice President
Date: August 2, 2002	Safeguard Scientifics (Delaware), Inc. By: /s/ N. Jeffrey Klauder ----- N. Jeffrey Klauder Vice President
Date: August 2, 2002	Safeguard 98 Capital L.P. By: Safeguard Delaware, Inc. Its: General Partner By: /s/ N. Jeffrey Klauder ----- N. Jeffrey Klauder Vice President

1. Safeguard Scientifics, Inc.

Safeguard Scientifics, Inc., a Pennsylvania corporation ("Safeguard"), owns all of the outstanding capital stock of Safeguard Delaware, Inc., a Delaware corporation ("SDI"), and Safeguard Scientifics (Delaware), Inc., a Delaware corporation ("SSD"). Safeguard has an address at 800 The Safeguard Building, 435 Devon Park Drive, Wayne, PA 19087-1945. Safeguard is a leader in building and operating technology companies in three principal areas: business and IT services, software and emerging technologies. See Schedule II with respect to the executive officers and directors of Safeguard as of the date of this amendment to Schedule 13D.
2. Safeguard Delaware, Inc.

SDI is a wholly owned subsidiary of Safeguard. SDI is a holding company and has an office at 103 Springer Building, 3411 Silverside Road, P.O. Box 7048, Wilmington, DE 19803. SDI is the general partner of Safeguard 98 Capital L.P. ("Safeguard 98"), a Delaware limited partnership. Schedule III provides information about the executive officers and directors of SDI as of the date of this amendment to Schedule 13D.
3. Safeguard Scientifics (Delaware), Inc.

SSD is a wholly owned subsidiary of Safeguard. SSD is a holding company and has an office at 103 Springer Building, 3411 Silverside Road, P.O. Box 7048, Wilmington, DE 19803. Schedule IV provides information about the executive officers and directors of SSD as of the date of this amendment to Schedule 13D.
4. Safeguard 98 Capital L.P.

Safeguard 98 is a Delaware limited partnership with a principal place of business at 103 Springer Building, 3411 Silverside Road, P.O. Box 7048, Wilmington, DE 19803.

SCHEDULE II
EXECUTIVE OFFICERS AND DIRECTORS OF SAFEGUARD SCIENTIFICS, INC.

Name ----	Present Principal Employment -----	Business Address -----
EXECUTIVE OFFICERS*		
Anthony L. Craig	President, Chief Executive Officer and Director	Safeguard Scientifics 800 The Safeguard Building 435 Devon Park Drive Wayne, PA 19087
Michael F. Cola	Managing Director, Corporate Operations	Safeguard Scientifics

Edgar Filing: CHROMAVISION MEDICAL SYSTEMS INC - Form SC 13D/A

		800 The Safeguard 435 Devon Park Dr Wayne, PA 19087
Robert D. Crowley	Managing Director, Software	Safeguard Scienti 800 The Safeguard 435 Devon Park Dr Wayne, PA 19087
Christopher J. Davis	Managing Director and Chief Financial Officer	Safeguard Scienti 800 The Safeguard 435 Devon Park Dr Wayne, PA 19087
Anthony A. Ibarguen	Managing Director, Business & IT Services	Safeguard Scienti 800 The Safeguard 435 Devon Park Dr Wayne, PA 19087
N. Jeffrey Klauder	Managing Director and General Counsel	Safeguard Scienti 800 The Safeguard 435 Devon Park Dr Wayne, PA 19087
DIRECTORS*		
Robert E. Keith, Jr.	Managing Director of TL Ventures and President and CEO, Technology Leaders Management, Inc.	TL Ventures 700 Building 435 Devon Park Dr Wayne, PA 19087
Anthony L. Craig Vincent G. Bell, Jr.	Same as above President and Chief Executive Officer, Verus Corporation	Same as above Verus Corporation 5 Radnor Corporat Suite 520 Radnor, PA 19087
Walter W. Buckley, III	Chairman and CEO, Internet Capital Group, Inc.	Internet Capital 435 Devon Park Dr Building 600 Wayne, PA 19087
Robert A. Fox	President, R.A.F. Industries	R.A.F. Industries One Pitcairn Pl, 165 Township Line Jenkintown, PA 19
Jack L. Messman	Chairman, President & CEO, Novell, Inc.	Novell, Inc. 1800 South Novell Provo, Utah 84606
Russell E. Palmer	Chairman and CEO, The Palmer Group	The Palmer Group 3600 Market Stree Philadelphia, PA
John W. Poduska Sr.	Consultant	295 Meadowbrook R Weston, MA 02493-

* All Executive Officers and Directors are U.S. Citizens.

Edgar Filing: CHROMAVISION MEDICAL SYSTEMS INC - Form SC 13D/A

SCHEDULE III
EXECUTIVE OFFICERS AND DIRECTORS OF SAFEGUARD DELAWARE, INC.

Name ----	Present Principal Employment -----	Busin -----
EXECUTIVE OFFICERS*		
Anthony L. Craig	President, Safeguard Delaware, Inc.; President and CEO, Safeguard Scientifics, Inc.	Safeguard Scienti 800 The Safeguard 435 Devon Park Dr Wayne, PA 19087
Christopher J. Davis	Vice President & Treasurer, Safeguard Delaware, Inc.; Managing Director and CFO, Safeguard Scientifics, Inc.	Safeguard Scienti 800 The Safeguard 435 Devon Park Dr Wayne, PA 19087
N. Jeffrey Klauder	Vice President & Assistant Secretary, Safeguard Delaware, Inc.; Managing Director and General Counsel, Safeguard Scientifics, Inc.	Safeguard Scienti 800 The Safeguard 435 Devon Park Dr Wayne, PA 19087
DIRECTORS*		
Deirdre Blackburn	Manager, Legal Systems & Corporate Secretary, Safeguard Scientifics, Inc.	Safeguard Scienti 800 The Safeguard 435 Devon Park Dr Wayne, PA 19087
Joseph R. DeSanto	Director, Safeguard Scientifics, Inc.	Safeguard Scienti 800 The Safeguard 435 Devon Park Dr Wayne, PA 19087
Tonya L. Zweier	Director, Safeguard Scientifics, Inc.	Safeguard Scienti 800 The Safeguard 435 Devon Park Dr Wayne, PA 19087

* All Executive Officers and Directors are U.S. Citizens.

Page 12 of 14

SCHEDULE IV
EXECUTIVE OFFICERS AND DIRECTORS OF SAFEGUARD SCIENTIFICS (DELAWARE), INC.

Name ----	Present Principal Employment -----	Busines -----
EXECUTIVE OFFICERS*		
Anthony L. Craig	President, Safeguard Scientifics (Delaware), Inc.; President and CEO, Safeguard Scientifics, Inc.	Safeguard Scienti 800 The Safeguard 435 Devon Park Dr Wayne, PA 19087
Christopher J. Davis	Vice President & Treasurer, Safeguard	Safeguard Scienti

Edgar Filing: CHROMAVISION MEDICAL SYSTEMS INC - Form SC 13D/A

	Scientifics (Delaware), Inc.; Managing Director and CFO, Safeguard Scientifics, Inc.	800 The Safeguard 435 Devon Park Dr Wayne, PA 19087
N. Jeffrey Klauder	Vice President & Assistant Secretary, Safeguard Scientifics (Delaware), Inc.; Managing Director and General Counsel, Safeguard Scientifics, Inc.	Safeguard Scientifics 800 The Safeguard 435 Devon Park Dr Wayne, PA 19087
DIRECTORS*		
Deirdre Blackburn	Manager, Legal Systems & Corporate Secretary, Safeguard Scientifics, Inc.	Safeguard Scientifics 800 The Safeguard 435 Devon Park Dr Wayne, PA 19087
Joseph R. DeSanto	Director, Safeguard Scientifics, Inc.	Safeguard Scientifics 800 The Safeguard 435 Devon Park Dr Wayne, PA 19087
Tonya L. Zweier	Director, Safeguard Scientifics, Inc.	Safeguard Scientifics 800 The Safeguard 435 Devon Park Dr Wayne, PA 19087

* All Executive Officers and Directors are U.S. Citizens.

Page 13 of 14

SCHEDULE V

All of the following transactions were effected by the executive officers and directors of the Reporting Persons listed below, in brokers' transactions in the Nasdaq National Market.

Name	Date	Type of Transaction	Shares	Price Per Share
----	----	-----	-----	-----

None

Page 14 of 14

EXHIBIT INDEX

EXHIBIT NO.	DESCRIPTION
-----	-----
99.13	Stock Purchase Agreement dated as of June ____, 2002 between Safeguard Delaware, Inc. and XL Vision, Inc.

